Catherine Skari
-
Jul- 2020 -9 JulyTIF News
TIF Position Statement on the Use of DEHP Plasticisers in Medical Devices
The safety concerns linked to the use of DEHP plasticizers, a manufactured chemical common in blood bags and PVC intravenous…
Read More » -
7 JulyNews
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe
Global Blood Therapeutics (GBT) plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (Voxelotor) be approved…
Read More » -
2 July
-
2 JulyTIF News
Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)
Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease…
Read More » -
1 JulyNews
Advances in the Care & Cure of Thalassaemia: New Hopes & Challenges
TIF, in collaboration with Thalassemics India and Thalassemia Patients Advovacy Group – India, conducted on June 12, 2020 a Webinar…
Read More » -
Jun- 2020 -30 JuneNews
European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia
Bristol Myers Squibb (BMS) & Acceleron Pharma announced today that the European Commission approved Reblozyl (luspatercept) for the treatment of Transfusion-Dependent…
Read More » -
29 June
-
25 June
-
22 JuneWebinars
COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patients from America
On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a…
Read More » -
19 JuneWebinars
COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients
An Expert Panel of Six Medical Professionals from various countries, such as India, the UK, Italy and Saudi Arabia, shared…
Read More »
